1. Home
  2. RDWR vs PHAT Comparison

RDWR vs PHAT Comparison

Compare RDWR & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDWR
  • PHAT
  • Stock Information
  • Founded
  • RDWR 1996
  • PHAT 2018
  • Country
  • RDWR Israel
  • PHAT United States
  • Employees
  • RDWR N/A
  • PHAT N/A
  • Industry
  • RDWR EDP Services
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDWR Technology
  • PHAT Health Care
  • Exchange
  • RDWR Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • RDWR 1.0B
  • PHAT 942.6M
  • IPO Year
  • RDWR 1999
  • PHAT 2019
  • Fundamental
  • Price
  • RDWR $22.95
  • PHAT $15.21
  • Analyst Decision
  • RDWR Hold
  • PHAT Strong Buy
  • Analyst Count
  • RDWR 3
  • PHAT 5
  • Target Price
  • RDWR $32.50
  • PHAT $17.60
  • AVG Volume (30 Days)
  • RDWR 219.6K
  • PHAT 982.1K
  • Earning Date
  • RDWR 10-29-2025
  • PHAT 10-30-2025
  • Dividend Yield
  • RDWR N/A
  • PHAT N/A
  • EPS Growth
  • RDWR N/A
  • PHAT N/A
  • EPS
  • RDWR 0.38
  • PHAT N/A
  • Revenue
  • RDWR $294,636,000.00
  • PHAT $147,190,000.00
  • Revenue This Year
  • RDWR $11.39
  • PHAT $218.38
  • Revenue Next Year
  • RDWR $7.43
  • PHAT $87.14
  • P/E Ratio
  • RDWR $59.78
  • PHAT N/A
  • Revenue Growth
  • RDWR 10.40
  • PHAT 460.30
  • 52 Week Low
  • RDWR $18.46
  • PHAT $2.21
  • 52 Week High
  • RDWR $31.57
  • PHAT $16.08
  • Technical
  • Relative Strength Index (RSI)
  • RDWR 43.08
  • PHAT 64.25
  • Support Level
  • RDWR $21.75
  • PHAT $14.61
  • Resistance Level
  • RDWR $22.85
  • PHAT $15.24
  • Average True Range (ATR)
  • RDWR 0.74
  • PHAT 0.82
  • MACD
  • RDWR 0.06
  • PHAT 0.02
  • Stochastic Oscillator
  • RDWR 60.63
  • PHAT 93.23

About RDWR Radware Ltd.

Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: